Table 5.
Comparison of adverse events between BJOE combined with chemotherapeutic agents versus chemotherapeutic agents alone
| Study | Myelotoxicity (%) | Nausea/vomiting (%) | Liver and renal injury (%) | Chest pain (%) | Fever (%) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Group 1 | Group 2 | Group 1 | Group 2 | Group 1 | Group 2 | Group 1 | Group 2 | Group 1 | Group 2 | |
| Lei H 2006 [14] | 9(29) | 22(73.3) | 5(16.1) | 12(40) | 3(9.7) | 5(16.7) | 3(9.7) | 4(13.3) | ||
| Wang H 2007 [15] | 9(25.7) | 21(60) | 2(5.7) | 5(14.3) | – | – | 1(2.9) | 1(2.9) | – | – |
| Fu X 2009 [17] | 15(25) | 36(60) | 4(6.67) | 12(20) | 1(1.7) | 2(3.3) | 3(5) | 8(13.3) | 3(5) | 11(18.33) |
| Chen Y 2011 [18] | 9(29.03) | 22(73.33) | 5(16.13) | 12(40) | – | – | 3(9.68) | 5(16.67) | 3(9.68) | 4(13.33) |
| Jia L 2011 [19] | 8(22.86) | 9(25.7) | 15(42.86) | 14(40) | – | – | – | – | – | – |
| Liu B 2012 [20] | 5(15.6) | 6(18.8) | 5(15.6) | 7(21.9) | 3(9.4) | 4(12.5) | 3(9.4) | 4(12.5) | 5(15.6) | 4(12.5) |
| Zhang J 2012 [21] | – | – | 2(7.14) | 6(16.6) | – | – | 0(0) | 3(8.3) | 3(10.7) | 11(30.6) |
| Zhang H 2013 [22] | – | – | – | – | – | – | 12(35.3) | 10(33.3) | – | – |
| Yang G 2014 [23] | 8(16.7) | 10(26.7) | 2(4.17) | 6(13.04) | – | – | 14(29.17) | 16(34.8) | – | – |
| Yang H 2014 [24] | 5(15.6) | 6(18.8) | 5(15.6) | 7(21.9) | 3(9.4) | 4(12.5) | – | – | 5(15.6) | 4(12.5) |
| Yue K 2016 [25] | 3 (5.0) | 9 (18) | 10(16.7) | 23 (46) | – | – | – | – | 8 (13.3) | 7(14) |
| P < 0.05 | P < 0.05 | P > 0.05 | P > 0.05 | P > 0.05 | ||||||
Values are given as number of patients (%).Group 1 Brucea javanica oil emulsion (BJOE) combined with chemotherapeutic agents; Group 2 Chemotherapeutic agents alone